Field Orthopaedics is pleased to announce that Patryk Kania has been appointed as the Company’s new Chief Executive Officer (CEO), succeeding Dr Christopher Jeffrey, who stepped aside as CEO and Board member by mutual agreement earlier this year. Patryk has been acting as CEO while the Board worked through Dr Jeffery’s contractual release, which has only just been completed.
Patryk brings significant commercial medical device and technology company experience. Prior to being a member of the Field Orthopaedics board and transitioning into the role of CEO, he held senior positions at Smith + Nephew, and its acquired company, Arthrocare, between 2016 and 2020. While there, he led Smith + Nephew’s transformation into the number one orthopaedic sports medicine company in ANZ.
Patryk also worked in various medical device and pharmaceutical positions at Abbott Vascular (2015- 2016), Johnson & Johnson (2005 – 2011) and Roche (2003-2005), in both Australia and Europe. He holds BBA and MBA degrees from Simon Fraser University, Vancouver, Canada.
Field now turns to harnessing the commercial transformation, technical innovation and product delivery, through renewed sales growth and outstanding surgeon support.
Quentin Flannery, Chairman of Field Orthopaedics, said: “On behalf of the Board, I am delighted to welcome Patryk as Field Orthopaedics’ new CEO. Patryk has made significant contributions as a member of the Board since early 2021, and we are excited to realise his leadership experience and track record of excellence in operations and execution for medical device businesses now as CEO. Patryk takes over at a key transition stage for the business as we work to expand our strategic market position within the hand orthopaedics segment. I’m confident in how he will use his energy and expertise to lead the team to deliver our sales transformation strategy.
I would like to thank Chris for his innovation and commitment to establishing the business over the past seven years, and for the important work he has done to prepare Field Orthopaedics for our next stage of development.”